Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the RATIONALE-301 study

Category Primary study
JournalJournal of Hepatology
Year 2023
This article has no abstract
Epistemonikos ID: eb3d74daeacd782033ced58543194e125fe656de
First added on: Dec 07, 2023